CD48 and Tumor Progression: The Critical Immunoregulatory Function

CD48, a cell surface glycoprotein belonging to the signaling lymphocytic activation molecule (SLAM) family, has emerged as a potential therapeutic target with significant clinical implications. In the context of cancer immunotherapy, CD48 plays a crucial role in immune evasion mechanisms and the modulation of immune responses. Engagement of CD48 with tumor-associated macrophages (TAMs) can influence their polarization towards an immunosuppressive M2-like phenotype, contributing to tumor progression. Inhibition of CD48-mediated interactions has the potential to enhance anti-tumor immune responses and improve the efficacy of immunotherapeutic approaches, including immune checkpoint blockade and CAR T cell therapy. Combination therapies, patient stratification based on biomarkers, and careful consideration of safety profiles are important aspects to be explored.